micro News and Research

RSS

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Genethon announces dosing of first patient at pediatric clinical trial platform for neuromuscular diseases

A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.

20 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

INTEGRA introduces its portable 96 channel pipette at the most affordable price

INTEGRA Biosciences has launched the MINI 96 portable electronic pipette, giving every lab access to significantly increased liquid handling productivity.

From INTEGRA Biosciences 20 Apr 2021

New nanomedicine device is effective for treating glioblastoma multiforme

A micro-sized polymeric net wrapping around brain tumors, just like a fishing net around a shoal of fish: this is the microMESH, a new nanomedicine device capable to conform around the surface of tumor masses and efficiently deliver drugs.

20 Apr 2021

New implantable tool images brain activity in 3D

Tools that allow neuroscientists to record and quantify functional activity within the living brain are in great demand. Traditionally, researchers have used techniques such as functional magnetic resonance imaging, but this method cannot record neural activity with high spatial resolution or in moving subjects.

20 Apr 2021

Researchers identify risk factors for SARS-CoV-2 reinfection

A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of SARS-CoV-2 infection among individuals who have recently recovered from COVID-19. The findings reveal that individuals with lower lymphocyte count or with two or fewer symptoms during the first COVID-19 episode are at higher risk of recurrent infection.

16 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

16 Apr 2021

Intestinal worm infection can cause severe sexually transmitted viral diseases

Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral in-fections to be much more severe elsewhere in the body.

16 Apr 2021

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

The corticosteroid budesonide shows promise in treating patients with mild COVID-19 infection. Interim analysis of the phase 3 PRINCIPLE clinical trial was posted to the medRxiv preprint server. Researchers found a 3-day faster recovery of COVID-19 symptoms in people at high risk for severe side effects administered a budesonide inhaler. There was also a 2.1% reduction in hospitalization and death.

14 Apr 2021

High recovery of top-quality purified RNA

Porvair Sciences has launched new kits for rapid extraction of total RNA from a wide range of biological samples. These proprietary kits enable extraction of up to 1000 µg of application-ready pure RNA in as little as 10 minutes.

From Chromatrap® - Porvair Sciences Ltd 14 Apr 2021

KA Imaging’s flat panel Sight™ receives medical device licence from Health Canada

KA Imaging’s Flat Panel Sight™ has received a Canadian Medical Device Licence from Health Canada. With the licence, the X-ray detector can be officially sold in Canada.

From KA Imaging 14 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

During the process of SARS-CoV-2 infection, once the virus penetrates the host cell, two open reading frames, ORF1a and ORF1ab, are translated. ORF1ab is responsible for the production of 16 nonstructural proteins (nsp). Several viral proteases such as 3CLpro and PLpro (papain-like protease) produce 1-16 nsps. A new study has been published in bioRxiv* preprint server, which deals with identifying drugs that are effective as PLpro inhibitors.

13 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

A team of scientists from the United Kingdom recently investigated the ultrastructural details of the attachment, entry, and budding processes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human airway epithelium. They have used a highly differentiated air-liquid interface cultures of airway epithelium to thoroughly investigate the viral infection cycle. The study is currently available on the bioRxiv* preprint server.

12 Apr 2021

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021

New technique can make X-rays more efficient at diagnosing bone and other injuries

A novel way to pinpoint and illuminate bone damage promises to make X-rays more efficient at diagnosing bone and other injuries, Flinders University researchers say.

9 Apr 2021

USC Stem Cell scientist receives $2.56 million NIH grant to explore 'synthetic' embryonic development

Whether in an earthworm or a human being, developmental processes are driven by complex networks of genetically-encoded signals that enable cells to take cues from each other and their environment.

8 Apr 2021

micro News and Research

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Genethon announces dosing of first patient at pediatric clinical trial platform for neuromuscular diseases

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

INTEGRA introduces its portable 96 channel pipette at the most affordable price

New nanomedicine device is effective for treating glioblastoma multiforme

New implantable tool images brain activity in 3D

Researchers identify risk factors for SARS-CoV-2 reinfection

Curcumin nanosystems could be powerful COVID-19 therapeutics

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

Intestinal worm infection can cause severe sexually transmitted viral diseases

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

High recovery of top-quality purified RNA

KA Imaging’s flat panel Sight™ receives medical device licence from Health Canada

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New technique can make X-rays more efficient at diagnosing bone and other injuries

USC Stem Cell scientist receives $2.56 million NIH grant to explore 'synthetic' embryonic development

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News